List of Excipients in Branded Drug ILEVRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	ILEVRO	nepafenac	0065-1750	BENZALKONIUM CHLORIDE	2032-03-31
Alcon Laboratories Inc	ILEVRO	nepafenac	0065-1750	BORIC ACID	2032-03-31
Alcon Laboratories Inc	ILEVRO	nepafenac	0065-1750	CARBOMER HOMOPOLYMER TYPE B	2032-03-31
Alcon Laboratories Inc	ILEVRO	nepafenac	0065-1750	CARBOXYMETHYLCELLULOSE SODIUM	2032-03-31
Alcon Laboratories Inc	ILEVRO	nepafenac	0065-1750	EDETATE DISODIUM	2032-03-31

ILEVRO Excipient Strategy, Formulation Patents, Generic Risk, and Commercial Opportunities

Last updated: August 11, 2026

ILEVRO is a once-daily ophthalmic suspension containing nepafenac 0.3% for the treatment of pain and inflammation associated with cataract surgery. Its commercial differentiation depends on more than the active ingredient. The formulation combines particle-size control, suspension stability, ocular tolerability, preservative protection, pH control, and multidose delivery in a product used around a high-volume surgical procedure.

The main commercial opportunity is to improve ILEVRO’s delivery platform rather than reproduce its composition. Potentially attractive positions include preservative-free single-dose packaging, lower-shake suspension systems, extended ocular residence, improved dosing uniformity, and combination products for cataract-surgery protocols.

What is ILEVRO and how is it formulated?

ILEVRO is nepafenac ophthalmic suspension, 0.3%, supplied as a multidose topical ophthalmic product. The product is administered once daily beginning one day before cataract surgery, continued on the day of surgery, and for the first 14 days after surgery, according to the FDA-approved labeling [1].

ILEVRO composition and excipient functions

The FDA label identifies the following inactive ingredients:

Excipient	Likely formulation role
Benzalkonium chloride 0.005%	Multidose antimicrobial preservative
Boric acid	Buffering and tonicity contribution
Carbomer 974P	Rheology modifier and suspension stabilizer
Glycerin	Tonicity adjustment and humectant function
Povidone	Wetting, viscosity, and particle-dispersion support
Sodium citrate dihydrate	Buffer component and pH control
Sodium hydroxide and/or hydrochloric acid	pH adjustment
Purified water	Vehicle

The labeled pH is approximately 7.0 to 7.5. The product is a suspension rather than a solution, so nepafenac particle attributes are central to dose uniformity, settling behavior, redispersibility, and ocular comfort [1].

Why the excipient system matters

Nepafenac has limited aqueous solubility. A suspension platform allows the drug to be delivered at the required concentration without relying on a high level of solubilizing excipients that could increase ocular irritation. The tradeoff is greater manufacturing and quality-control complexity.

The carbomer-povidone system can support particle suspension and improve wetting. Glycerin contributes to tonicity. Borate and citrate components help maintain pH during storage and use. Benzalkonium chloride enables multidose packaging but creates a potential opportunity for preservative-free reformulation.

The formulation must balance four competing requirements:

1. Physical stability during shelf life.
2. Rapid and consistent redispersion after shaking.
3. Uniform drug concentration throughout the bottle.
4. Acceptable ocular tolerability after surgery.

A formulation that increases viscosity may reduce settling but can impair drop formation, dosing accuracy, or patient comfort. A lower-viscosity formulation may improve administration but increase sedimentation and dose variability.

What excipients are most commercially important in ILEVRO?

The highest-value excipient opportunities are associated with suspension control, preservative replacement, and delivery-device performance.

Carbomer 974P and rheology control

Carbomer 974P is the most technically important structural excipient in the formulation. It can increase viscosity and create a yield-stress system that slows particle settling. Its concentration, neutralization state, hydration profile, and interaction with nepafenac particles influence:

• Sedimentation rate.
• Sediment compactness.
• Redispersibility.
• Drop size.
• Ocular residence time.
• Container-to-container dose consistency.

A substitute polymer could create a meaningful product distinction if it maintains suspension performance with lower viscosity or better ocular comfort. Candidate platforms may include low-viscosity carbomers, cellulose derivatives, polyvinyl alcohol systems, poloxamers, or engineered polymer-particle systems. Any substitution would require comparative data on particle distribution, viscosity, redispersibility, preservative effectiveness, and stability.

Povidone and particle wetting

Povidone can support wetting and dispersion of hydrophobic drug particles. Poor wetting can cause floating particles, agglomeration, slow redispersion, and nonuniform dosing. The commercial opportunity is to optimize wetting without creating excessive foaming, viscosity, or compatibility problems with the preservative system.

Surface treatment of nepafenac particles may provide an alternative route. Micronization, controlled crystallization, spray drying, or particle engineering could reduce reliance on high polymer levels. These approaches may create manufacturing know-how and process barriers even when the final excipient list is not novel.

Benzalkonium chloride and preservative-free opportunities

Benzalkonium chloride is effective in multidose ophthalmic products but has recognized tolerability concerns, particularly with repeated exposure and compromised ocular surfaces. Cataract patients often receive several topical products, which increases interest in reducing total preservative exposure.

A preservative-free ILEVRO-like product could use:

• Unit-dose vials.
• Multidose bottles with validated preservative-free closure technology.
• One-way valve systems.
• Container designs that limit microbial ingress.
• Alternative preservatives, subject to ophthalmic safety and regulatory acceptance.

Preservative removal is not a simple substitution. The manufacturer must demonstrate microbiological integrity, in-use stability, extractables and leachables control, and dose uniformity across the intended use period. A preservative-free suspension also presents greater microbial and physical-stability risk than a preserved product.

What formulation patents may protect an ILEVRO-like product?

Formulation protection can extend beyond the named drug substance. An ILEVRO-like product may be protected through claims directed to:

• Nepafenac concentration.
• Particle-size distribution.
• Crystalline form or polymorph.
• Carbomer or polymer concentration.
• Viscosity range.
• pH and osmolality.
• Preservative concentration.
• Redispersibility.
• Suspension stability.
• Multidose packaging.
• Dosing frequency.
• Use after cataract surgery.

The most defensible formulation claims usually require measurable technical parameters. Broad claims covering nepafenac in an ophthalmic suspension may face greater validity and freedom-to-operate pressure if similar formulations were publicly known.

Patent-strength assessment

The formulation estate is stronger when the claims combine several limitations that are difficult to design around, such as:

• A defined nepafenac particle-size distribution.
• A narrow viscosity or yield-stress range.
• Specific polymer and buffer concentrations.
• Demonstrated reduction in settling or improved dose uniformity.
• A defined container-closure system.
• Clinical or comparative evidence showing improved tolerability or efficacy.

Claims limited only to conventional ophthalmic excipients may be more vulnerable to obviousness challenges, particularly where the excipient performs a standard function. Manufacturing-process claims can be stronger if they produce a distinctive particle morphology or a reproducible stability advantage.

When does ILEVRO lose exclusivity?

ILEVRO received FDA approval in 2012 under NDA 203794. Nepafenac was previously approved in the United States in the lower-strength product NEVANAC, so ILEVRO was not a new active ingredient launch [1][2].

The relevant exclusivity and patent questions are separate:

Protection category	ILEVRO relevance
New chemical entity exclusivity	Generally not available because nepafenac was previously approved
New clinical investigation exclusivity	May apply to a qualifying new strength or formulation, subject to FDA determination
Orange Book patents	Determine whether an ANDA applicant must certify or address listed patents
Formulation patents	May cover suspension composition, particle attributes, or manufacturing
Method-of-use patents	May cover perioperative cataract-surgery use or dosing
Regulatory exclusivity	Depends on the FDA exclusivity code and approval history

The FDA Orange Book is the controlling public source for currently listed patents and expiration data [2]. A commercial diligence review should distinguish listed patents for the reference product from expired patents, delisted patents, and patents that do not block an ANDA because of claim scope.

What is the Orange Book and Paragraph IV risk for ILEVRO?

An ANDA applicant seeking approval of a nepafenac ophthalmic suspension would need to address the reference-listed drug’s Orange Book patents through one of the statutory certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV filing can create litigation risk under the Hatch-Waxman framework. If the patent holder sues within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments [3].

Generic launch scenarios

Scenario	Commercial implication
No unexpired blocking patent	Generic approval and launch can proceed after regulatory requirements are satisfied
Paragraph III certification	Approval is deferred until the listed patent expires
Paragraph IV certification without timely litigation	The applicant may proceed after applicable FDA review requirements
Paragraph IV litigation with a 30-month stay	Launch timing depends on litigation outcome, settlement, and FDA action
First approved ANDA with qualifying Paragraph IV	Potential 180-day generic exclusivity may apply
Formulation redesign	A competitor may avoid selected claims but incur development and comparability risk

For ophthalmic suspensions, the regulatory burden can exceed that of a simple ophthalmic solution. The applicant must establish pharmaceutical equivalence, including active ingredient, dosage form, route, strength, and performance characteristics. In vitro studies may be important for particle size, viscosity, pH, osmolality, dose uniformity, and redispersibility.

What FDA regulatory issues affect ILEVRO excipient competition?

A generic or follow-on product must address excipient differences carefully. FDA may accept differences in inactive ingredients when they are suitable for the dosage form and do not affect safety or efficacy. Ophthalmic products receive close scrutiny because excipients contact sensitive ocular tissue and may affect tolerability or postoperative healing.

Key development studies include:

• Particle-size distribution and morphology.
• Drug-content uniformity.
• Shake and redispersion testing.
• Sedimentation and caking behavior.
• Rheology across temperature ranges.
• Preservative effectiveness testing.
• Sterility assurance.
• Container-closure integrity.
• Extractables and leachables.
• In-use stability.
• Comparative in vitro release or performance testing.

A preservative-free version may require a different regulatory package because packaging becomes part of the antimicrobial-control strategy. A new delivery device may also create combination-product and human-factors requirements.

What commercial opportunities exist around ILEVRO excipients?

Preservative-free postoperative NSAID

The clearest commercial opportunity is a preservative-free nepafenac suspension for patients with ocular-surface sensitivity or high cumulative exposure to preserved drops. The product could command a premium if it demonstrates comparable efficacy, tolerability, and practical administration.

Improved suspension technology

A lower-shake or easy-redispersion product could reduce patient-use errors. Patients may fail to shake suspensions adequately, creating variable dosing. A formulation that remains homogeneous longer or redistributes with fewer inversions could support differentiation.

Combination cataract-surgery products

Cataract surgery commonly involves an antibiotic, corticosteroid, and NSAID. Combination or co-packaged regimens could reduce complexity. A fixed-dose combination would face compatibility, stability, dose-flexibility, and regulatory challenges. Co-packaging may provide a faster commercial path while preserving separate formulations.

Extended-residence delivery

In situ gels, mucoadhesive systems, drug-loaded particles, and depot inserts could reduce dosing frequency. These platforms would compete with the convenience of once-daily ILEVRO, so the commercial value would depend on improved adherence, reduced postoperative medication burden, or lower total treatment cost.

Contract manufacturing and excipient supply

Specialized suppliers can pursue value through:

• Ophthalmic-grade polymers.
• Surface-modified nepafenac particles.
• Sterile excipient systems.
• Preservative-free multidose packaging.
• Suspension-process development.
• Analytical methods for particle and dose characterization.

The strongest supplier positions will be based on validated performance and regulatory documentation rather than commodity excipient availability.

How does ILEVRO compare with NEVANAC and generic nepafenac?

Product	Active ingredient	Strength	Dosage form	Dosing profile
NEVANAC	Nepafenac	0.1%	Ophthalmic suspension	More frequent dosing under labeling
ILEVRO	Nepafenac	0.3%	Ophthalmic suspension	Once daily perioperative regimen
Generic nepafenac products	Nepafenac	Usually strength-specific	Ophthalmic suspension	Depends on approved product

ILEVRO’s principal product-level advantage is the 0.3% strength and once-daily regimen. A competitor that matches the active ingredient and strength but offers better tolerability, easier redispersion, preservative-free delivery, or lower acquisition cost could target the same surgical pathway.

What manufacturing and intellectual-property barriers exist?

The largest barriers are process control and product performance. A manufacturer must consistently produce sterile nepafenac particles with controlled size, morphology, crystallinity, and surface properties. It must then maintain those attributes during compounding, filling, shipping, and storage.

Potentially protectable manufacturing steps include:

• Controlled crystallization.
• Wet or dry micronization.
• Particle-surface modification.
• Polymer-assisted dispersion.
• Sterile milling or aseptic processing.
• Specialized homogenization.
• In-process particle-size controls.
• Packaging processes that limit settling or contamination.

Geographic protection depends on national patent filings and remaining term. U.S. Orange Book listings are relevant to ANDA timing, while European, Japanese, and other national patents may create separate market-entry constraints. Regulatory approval, reimbursement, surgeon adoption, and distribution agreements can remain commercial barriers after patent expiry.

Key Takeaways

• ILEVRO is a nepafenac 0.3% ophthalmic suspension approved for perioperative cataract-surgery use.
• Its excipient system centers on carbomer 974P, povidone, borate/citrate buffering, glycerin, and benzalkonium chloride.
• The main technical challenges are suspension stability, redispersibility, dose uniformity, sterility, and ocular tolerability.
• Preservative-free delivery is the most direct commercial opportunity.
• Particle engineering, lower-shake formulations, multidose preservative-free packaging, and postoperative co-packaging are credible differentiation routes.
• ILEVRO did not introduce a new active ingredient, so NCE exclusivity is not the central protection mechanism.
• Orange Book patents, formulation claims, method-of-use claims, and manufacturing know-how determine generic launch risk.
• An ANDA applicant may use Paragraph IV certification, but litigation can delay approval through the Hatch-Waxman process.
• The strongest formulation patents will tie composition to measurable performance, such as particle size, viscosity, redispersibility, or stability.
• Generic competition is likely to focus on regulatory equivalence and manufacturing efficiency, while branded reformulation opportunities depend on tolerability and convenience.

FAQs About ILEVRO Excipient and Commercial Strategy

Is benzalkonium chloride in ILEVRO?

Yes. The FDA label identifies benzalkonium chloride at 0.005% as an inactive ingredient and preservative in ILEVRO [1].

Can ILEVRO be reformulated without carbomer?

Potentially, but the replacement must preserve suspension stability, dose uniformity, redispersibility, sterility, and ocular tolerability. Removing carbomer without replacing its rheological function would create a material product-performance risk.

Is a preservative-free nepafenac product commercially attractive?

Yes. A preservative-free product could target patients with ocular-surface sensitivity and reduce cumulative preservative exposure. The primary development challenge is maintaining microbiological integrity in a suspension product.

Would a nepafenac solution be easier to approve than a suspension?

Not necessarily. A solution could simplify dose uniformity and redispersion, but nepafenac solubility, solvent tolerability, chemical stability, and precipitation risk would become central development issues.

Can an excipient supplier obtain patent protection for an ILEVRO-like formulation?

Yes, if the formulation or process has patentable novelty and non-obvious technical advantages. Protection is stronger when the claims cover defined particle attributes, rheological behavior, stability results, or a specialized container-closure system rather than only conventional excipient selection.

References

1. U.S. Food and Drug Administration. (2012). ILEVRO (nepafenac ophthalmic suspension) 0.3% prescribing information. Alcon Laboratories, Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman letters. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters